Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,757 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,046)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01733589 | Recombinant Human Endostatin Continued Pumping Into Vein Combining With CCRT in Unresectable Stage III NSCLC | completed | Phase 1 / Phase 2 | 73 | Zhejiang Cancer HospitalOTHER | 1 | Jul 14, 2017 | clinicaltrials |
| NCT02300831 | LUMINIST: LUng Cancer Molecular Insights Non Interventional Study(LUMINIST) | completed | — | 770 | AstraZenecaINDUSTRY | 23 | Jul 14, 2017 |
| NCT01909752 | Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer | completed | Phase 2 | 12 | UbiVacINDUSTRY | 1 | Jul 6, 2017 | clinicaltrials |
| NCT01051934 | A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma | completed | Phase 1 | 2 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01807546 | Oral Rigosertib for Squamous Cell Carcinoma | completed | Phase 2 | 64 | Traws Pharma, Inc.INDUSTRY | 1 | Jun 26, 2017 | clinicaltrials |
| NCT01233687 | AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 49 | Ahmad TarhiniOTHER | 1 | Jun 22, 2017 | clinicaltrials |
| NCT02064491 | Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC | completed | Phase 2 | 18 | Finnish Lung Cancer GroupOTHER | 1 | Jun 22, 2017 | clinicaltrials |
| NCT01685060 | LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib | completed | Phase 2 | 140 | Novartis PharmaceuticalsINDUSTRY | 12 | Jun 19, 2017 | clinicaltrials |
| NCT01948141 | Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens | completed | Phase 2 | 6 | Roswell Park Cancer InstituteOTHER | 1 | Jun 8, 2017 | clinicaltrials |
| NCT01363947 | Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer | completed | Phase 1 | 87 | Genentech, Inc.INDUSTRY | 2 | Jun 7, 2017 | clinicaltrials |
| NCT01190527 | Using FDG-PET During Radiation Therapy in Non-Small Cell Lung Cancer(HUM15709) | completed | N/A | 42 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jun 2, 2017 | clinicaltrials |
| NCT03170284 | Observational Study to Evalute the Efficacy and Safety of Avastin (Bevacizumab) in Addition to Platinum-Based Chemotherapy for First-Line Treatment of Participants With Non-Small Cell Lung Cancer(AVALANCHE) | completed | — | 150 | Hoffmann-La RocheINDUSTRY | 1 | May 31, 2017 | clinicaltrials |
| NCT00942825 | Triplet Combination First Line Treatment in Non Small Cell Lung Cancer (NSCLC)(CBP08-02) | completed | Phase 2 | 195 | CanBas Co. Ltd.INDUSTRY | 1 | May 24, 2017 | clinicaltrials |
| NCT01360554 | ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer(ARCHER 1009) | completed | Phase 3 | 878 | PfizerINDUSTRY | 23 | May 24, 2017 | clinicaltrials |
| NCT01438307 | Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 28 | University of Alabama at BirminghamOTHER | 1 | May 24, 2017 | clinicaltrials |
| NCT01166204 | Concurrent and Non-concurrent Chemo-radiotherapy or Radiotherapy Alone With Intensity-modulated Radiotherapy (IMRT) for Non Small Cell Lung Cancer (NSCLC) to an Individualised Mean Lung Dose (MLD) | completed | Phase 2 | 300 | Maastricht Radiation OncologyOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT00480831 | A Study of PRO95780 in Patients With Previously Untreated, Advanced-Stage Non-Small Cell Lung Cancer (APM4074g) | completed | Phase 2 | 128 | Genentech, Inc.INDUSTRY | 0 | May 18, 2017 | clinicaltrials |
| NCT03157310 | Bone Metastasis on the Survival of Gefitinib Effective Patients | completed | N/A | 265 | Qilu Hospital of Shandong UniversityOTHER | 0 | May 17, 2017 | clinicaltrials |
| NCT00076856 | Temozolomide for Treatment of Brain Metastases From Non-Small Cell Lung Cancer (Study P03247) | completed | Phase 2 | 95 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 9, 2017 | clinicaltrials |
| NCT00831545 | Study to Evaluate the Efficacy and Safety of Temozolomide in Subjects With Brain Metastases of Either Malignant Melanoma, Breast, or Non-small Cell Lung Cancer (P02064) | completed | Phase 2 | 162 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 9, 2017 | clinicaltrials |
| NCT01023347 | A Trial of Paclitaxel (Genexol®) and Cisplatin Versus Paclitaxel Loaded Polymeric Micelle (Genexol-PM®) and Cisplatin in Advanced Non Small Cell Lung Cancer | completed | Phase 2 | 276 | Samyang Biopharmaceuticals CorporationINDUSTRY | 1 | May 9, 2017 | clinicaltrials |
| NCT02658747 | Neutropenic Sepsis in Patients With Non-Small Cell Lung Cancer Treated With Single-Agent Docetaxel and Associated Resource Use in the UK | completed | — | 120 | Hoffmann-La RocheINDUSTRY | 1 | May 8, 2017 | clinicaltrials |
| NCT03141957 | Hypermetabolism in the Elderly Lung Cancer Patient(HELP) | completed | — | 27 | University of Paris 5 - Rene DescartesOTHER | 1 | May 8, 2017 | clinicaltrials |
| NCT00188214 | CT Perfusion Scans for Assessment of Lung Cancer Before and After Chemo +/- Radiotherapy | completed | Phase 2 | 38 | University Health Network, TorontoOTHER | 1 | May 4, 2017 | clinicaltrials |
| NCT00372203 | Endobronchial Ultrasound vs Mediastinoscopy in NSCLC | completed | Phase 2 | 200 | University Health Network, TorontoOTHER | 1 | May 4, 2017 | clinicaltrials |
| NCT00731952 | Phase I Study of Induction Therapy With VELCADE and Vorinostat in Patients With Surgically Resectable Non-Small Cell Lung Cancer | completed | Phase 1 | 21 | University of VirginiaOTHER | 1 | May 4, 2017 | clinicaltrials |
| NCT01836133 | An Observational Study of Tarceva (Erlotinib) in Participants With Locally Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer (ELEMENT)(ELEMENT) | completed | — | 70 | Hoffmann-La RocheINDUSTRY | 1 | May 4, 2017 | clinicaltrials |
| NCT00408460 | Imatinib Mesylate and Paclitaxel in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 34 | University of WashingtonOTHER | 1 | Apr 25, 2017 | clinicaltrials |
| NCT01493843 | Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer | completed | Phase 2 | 501 | Genentech, Inc.INDUSTRY | 16 | Apr 25, 2017 | clinicaltrials |
| NCT02679443 | Vitamin Supplementation in NSCLC Patients on Pemetrexed Based Chemotherapy(PEMVITASTART) | completed | N/A | 161 | Post Graduate Institute of Medical Education and Research, ChandigarhOTHER | 1 | Apr 25, 2017 | clinicaltrials |
| NCT01999673 | Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer(SUNRISE) | completed | Phase 3 | 582 | Peregrine PharmaceuticalsINDUSTRY | 14 | Apr 21, 2017 | clinicaltrials |
| NCT01138163 | Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer | completed | Phase 2 | 121 | Peregrine PharmaceuticalsINDUSTRY | 5 | Apr 19, 2017 | clinicaltrials |
| NCT01160601 | Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer | completed | Phase 2 | 86 | Peregrine PharmaceuticalsINDUSTRY | 5 | Apr 19, 2017 | clinicaltrials |
| NCT03117335 | Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung Cancer | completed | Phase 3 | 560 | Jiangsu Wuzhong Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 17, 2017 | clinicaltrials |
| NCT00622193 | Dose Range Study of Anamorelin in Patients With Non-small Cell Lung Cancer | completed | Phase 2 | 228 | Helsinn Therapeutics (U.S.), IncINDUSTRY | 2 | Apr 14, 2017 | clinicaltrials |
| NCT02171286 | The Oncopanel Pilot (TOP) Study | completed | — | 432 | British Columbia Cancer AgencyOTHER | 1 | Apr 14, 2017 | clinicaltrials |
| NCT01153984 | A Study to Assess Biomarkers Impact on Participants Response to Erlotinib Treatment for First-line Non-Small Cell Lung Cancer With Endothelial Growth Factor Receptor (EGFR) Activating Mutations(BIOTEC) | completed | Phase 2 | 23 | Hoffmann-La RocheINDUSTRY | 1 | Apr 13, 2017 | clinicaltrials |
| NCT01951690 | Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer | completed | Phase 2 | 55 | Verastem, Inc.INDUSTRY | 1 | Apr 13, 2017 | clinicaltrials |
| NCT00642759 | Carboplatin, Abraxane, and Bevacizumab in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 36 | Massachusetts General HospitalOTHER | 1 | Apr 7, 2017 | clinicaltrials |
| NCT02369198 | MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC | completed | Phase 1 | 27 | Asbestos Diseases Research FoundationOTHER | 1 | Apr 7, 2017 | clinicaltrials |
| NCT01726296 | Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care | completed | N/A | 1,440 | Fox Chase Cancer CenterOTHER | 1 | Apr 6, 2017 | clinicaltrials |
| NCT01085136 | LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib | completed | Phase 3 | 1,154 | Boehringer IngelheimINDUSTRY | 23 | Apr 4, 2017 | clinicaltrials |
| NCT00453362 | A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib | completed | Phase 1 / Phase 2 | 88 | Genentech, Inc.INDUSTRY | 0 | Mar 31, 2017 | clinicaltrials |
| NCT00854308 | A Study of MetMAb Administered to Patients With Advanced Non-Small Cell Lung Cancer, in Combination With Tarceva (Erlotinib) | completed | Phase 2 | 137 | Genentech, Inc.INDUSTRY | 0 | Mar 31, 2017 | clinicaltrials |
| NCT02044380 | Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations | completed | Phase 3 | 14 | Boehringer IngelheimINDUSTRY | 1 | Mar 31, 2017 | clinicaltrials |
| NCT00499655 | Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer | completed | Phase 2 | 107 | City of Hope Medical CenterOTHER | 1 | Mar 29, 2017 | clinicaltrials |
| NCT02475720 | Survey on the Treatment Reality of Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Non-small Cell Lung Cancer(NSCLC) | completed | — | 2,000 | AstraZenecaINDUSTRY | 1 | Mar 27, 2017 | clinicaltrials |
| NCT00215930 | The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 53 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 23, 2017 | clinicaltrials |
| NCT00963807 | A Comparison of FLT to FDG PET/CT in the Early Assessment of Chemotherapy Response in Stage IB-IIIA Resectable NSCLC | completed | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 1 | Mar 17, 2017 | clinicaltrials |
Data updated 24 days agoSource updated Jul 14, 2017source: clinicaltrials